Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

October 2025

Sonelokimab, an IL-17A- and IL-17F- inhibiting nanobody for active psoriatic arthritis: A randomized, placebo-controlled Phase 2 trial

Nat Med 2025; doi.10.1038/s41591-025-03971-6. Epub ahead of print

Ogdie A,

Eder L,

Reich K,

In this first global clinical study of a nanobody in inflammatory arthritis, sonelokimab, an
IL-17A- and IL-17F-inhibiting nanobody demonstrated strong efficacy across multiple domains including high-hurdle composite joint and skin responses. McInnes et al. reported on the Phase 2, randomized, double-blind, PBO-controlled ARGO trial which evaluated the efficacy and safety of sonelokimab in patients with active PsA.

Keywords:

July 2025

Ixekizumab and malignant neoplasms A pooled analysis of data from 25 randomized clinical trials

Merola et al. JAMA Dermatol 2025; 9:e252056

Papp KA,

Zhu D,

Inman E,

Grace E,

Merola et al. showed that the safety profile of ixekizumab (IXE) supports its long-term use in patients with PsO, PsA, or axSpA, without an increased risk for malignant neoplasm development. Merola et al. investigated the incidence rates of malignant neoplasms among patients with PsO, PsA, or axSpA who underwent long-term treatment with IXE, an IL- 17A antagonist.

Keywords:

June 2025

Deucravacitinib in patients with plaque psoriasis who screened positive for psoriatic arthritis: improvements in joint pain and the impact of musculoskeletal symptoms

Dermatol Ther (Heidelb) 2025 DOI: 10.1007/s13555-025-01428-9

Varga S,

Choi JC,

Zhong Y,

Bili A,

Merola et al. undertook a post hoc analysis of prospective cohorts that compared the effects of deucravacitinib vs placebo and vs apremilast on joint pain, and the impact of musculoskeletal symptoms, at Weeks 16 and 24 in the pooled POETYK PSO-1 and PSO-2 populations who self-reported joint symptoms on the PASE questionnaire. Patients who screened positively for PsA reported greater improvements in joint pain and peripheral joint disease with deucravacitinib vs placebo at Week 16 and vs apremilast at Week 24. Findings from this pooled analysis suggest that deucravacitinib may be used to treat both dermatologic and joint symptoms effectively in patients with psoriasis and probable arthritis.